semaglutide weight loss hendersonville tn Management / GLP-1 Therapy in Semaglutide in Franklin | IntraVenous

Inflectra (the first biosimilar drug) was approved by the FDA in 2016, and Ixifi (the second biosimilar drug) in 2017

Whilst all agents in this class can cause nausea, individual responses vary: Dulaglutide (Trulicity) is administered once weekly and some patients report fewer gastrointestinal effects Liraglutide (Victoza) requires daily injection but allows more gradual dose titration Exenatide (Byetta, Bydureon) is available in both short-acting (twice daily) and extended-release (once weekly) formulations Switching between GLP-1 agonists should be undertaken under medical supervision with appropriate dose adjustment and monitoring

She says K Health, for example, has strict criteria for prescribing GLP-1 agonist medications to ensure theyre only going to patients who really need them

CONCLUSIONS CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported